[
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?",
    "summary": "We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market […]",
    "url": "https://finnhub.io/api/news?id=9badcf5c34672d2b56494ae78649d55e1a8ce282bd20979735db7b2028bbcf06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743203219,
      "headline": "Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?",
      "id": 133527617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market […]",
      "url": "https://finnhub.io/api/news?id=9badcf5c34672d2b56494ae78649d55e1a8ce282bd20979735db7b2028bbcf06"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know",
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=7af7b2a34767f471f366974794765be6dbed16685dcd5cf932d6bc5129de8695",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743198610,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know",
      "id": 133527618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=7af7b2a34767f471f366974794765be6dbed16685dcd5cf932d6bc5129de8695"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces Program Updates for Type 1 Diabetes Portfolio",
    "summary": "BOSTON, March 28, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) portfolio.",
    "url": "https://finnhub.io/api/news?id=c06c7862cd3a0c2dc617359905daa3280a547c2fae2d5395681dd5d471e4ccd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743192300,
      "headline": "Vertex Announces Program Updates for Type 1 Diabetes Portfolio",
      "id": 133527619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, March 28, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) portfolio.",
      "url": "https://finnhub.io/api/news?id=c06c7862cd3a0c2dc617359905daa3280a547c2fae2d5395681dd5d471e4ccd4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex to Cease Clinical Trials on Diabetes Treatment",
    "summary": "By Katherine Hamilton Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement. There were...",
    "url": "https://finnhub.io/api/news?id=cf5a1722c09f6ba92e0d70751ee4b530eb475b595809cc01c821d5bcbda0c4c8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743181507,
      "headline": "Vertex to Cease Clinical Trials on Diabetes Treatment",
      "id": 133524919,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement. There were...",
      "url": "https://finnhub.io/api/news?id=cf5a1722c09f6ba92e0d70751ee4b530eb475b595809cc01c821d5bcbda0c4c8"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4bfdcae8d90a2ec98cb6fc2f2a83725379271d65abc34a0de02a92bf6725ddd4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743179820,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "id": 133638618,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4bfdcae8d90a2ec98cb6fc2f2a83725379271d65abc34a0de02a92bf6725ddd4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing",
    "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS INC - EXPECTS $400 MILLIONIMPAIRMENTCHARGE FOR VX-264 - SEC FILINGSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=f4f76b952b7a494462e45c9a26281d8f9f0a6489a642de0f7154daad5c0003a9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743178319,
      "headline": "Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing",
      "id": 133524671,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS INC - EXPECTS $400 MILLIONIMPAIRMENTCHARGE FOR VX-264 - SEC FILINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=f4f76b952b7a494462e45c9a26281d8f9f0a6489a642de0f7154daad5c0003a9"
    }
  },
  {
    "ts": null,
    "headline": "Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession",
    "summary": "The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession.  If you're wondering which stocks might do well even if the U.S. economy slumps, you may want to look back to see which ones thrived during the last prolonged recession -- the Great Recession, which took place between December 2007 and June 2009.  The S&P 500 fell by 36% during that period.",
    "url": "https://finnhub.io/api/news?id=bf04ebd697f9cdeb2e0e69ac7a019179d226177ea3e9cfdec17e74a71d17357e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743157800,
      "headline": "Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession",
      "id": 133507752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession.  If you're wondering which stocks might do well even if the U.S. economy slumps, you may want to look back to see which ones thrived during the last prolonged recession -- the Great Recession, which took place between December 2007 and June 2009.  The S&P 500 fell by 36% during that period.",
      "url": "https://finnhub.io/api/news?id=bf04ebd697f9cdeb2e0e69ac7a019179d226177ea3e9cfdec17e74a71d17357e"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Growth ESG Portfolios Q4 2024 Commentary",
    "summary": "A market broadening in the fourth quarter sparked by Donald Trumpâs election victory and a further interest rate cut from the US Federal Reserve proved momentum-driven and short-lived.",
    "url": "https://finnhub.io/api/news?id=6b0ea926305a2a4ba933c3161d88aa79688369656de128124c20e105b3f2a570",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743123300,
      "headline": "ClearBridge Growth ESG Portfolios Q4 2024 Commentary",
      "id": 133504563,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054522581/image_2054522581.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "A market broadening in the fourth quarter sparked by Donald Trumpâs election victory and a further interest rate cut from the US Federal Reserve proved momentum-driven and short-lived.",
      "url": "https://finnhub.io/api/news?id=6b0ea926305a2a4ba933c3161d88aa79688369656de128124c20e105b3f2a570"
    }
  }
]